Comparative Pharmacology
Head-to-head clinical analysis: NOVAFED versus SUDAFED 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVAFED versus SUDAFED 12 HOUR.
NOVAFED vs SUDAFED 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Novafed contains pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.
1-2 capsules orally every 12 hours; each capsule contains pseudoephedrine HCl 120 mg and dextromethorphan HBr 30 mg.
120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.
None Documented
None Documented
Terminal elimination half-life: 4-8 hours (mean 5-6 hours); prolonged in renal impairment (up to 20 hours) and with urinary alkalinization; in patients with normal renal function, steady-state is achieved after 2-3 days of every-6-hour dosing.
8-10 hours in adults with normal renal function; prolonged to 19-24 hours in renal impairment (CrCl <30 mL/min); shorter in children (3-4 hours)
Renal elimination of unchanged drug and metabolites; approximately 60-70% of a dose is excreted in urine as unchanged pseudoephedrine within 24 hours; the remainder is metabolized hepatically and excreted renally; minimal biliary/fecal elimination (<5%).
Renal: 74-95% as unchanged drug; 1-4% as active metabolite (norpsuedoephedrine); biliary/fecal: minimal (<1%)
Category C
Category C
Decongestant
Decongestant